Johnson KD - Search Results

1

Health economic evaluation of introducing a PPSV23-based vaccination programme to adults aged 65 and above, and an extension to the 60-64 age group in Denmark.

Birck AM, Nordin Christensen L, Pedersen MH, Olsen J, Johnson KD, Bencina G, Clausen TH, Larsen CS. Birck AM, et al. Among authors: johnson kd. Expert Rev Vaccines. 2021 Oct;20(10):1327-1337. doi: 10.1080/14760584.2021.1977627. Epub 2021 Sep 16. Expert Rev Vaccines. 2021. PMID: 34488534

2

Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence.

Niederman MS, Folaranmi T, Buchwald UK, Musey L, Cripps AW, Johnson KD. Niederman MS, et al. Among authors: johnson kd. Expert Rev Vaccines. 2021 Mar;20(3):243-256. doi: 10.1080/14760584.2021.1880328. Epub 2021 Feb 20. Expert Rev Vaccines. 2021. PMID: 33478306 Review.

3

Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature.

Cripps AW, Folaranmi T, Johnson KD, Musey L, Niederman MS, Buchwald UK. Cripps AW, et al. Among authors: johnson kd. Expert Rev Vaccines. 2021 Mar;20(3):257-267. doi: 10.1080/14760584.2021.1889374. Epub 2021 Mar 2. Expert Rev Vaccines. 2021. PMID: 33567914 Review.

4

Pneumococcal vaccination coverage among adults aged 19 to 64 years with immuno-compromising conditions, cerebrospinal fluid (CSF) leaks, or cochlear implants in the US.

Deb A, Mohanty S, Ou W, Rajagopalan S, Johnson KD. Deb A, et al. Among authors: johnson kd. Expert Rev Vaccines. 2021 Mar;20(3):331-345. doi: 10.1080/14760584.2021.1898377. Epub 2021 Apr 8. Expert Rev Vaccines. 2021. PMID: 33724134

5

Cost and health impact analysis of herpes zoster vaccination in Norway.

Flem E, Graham J, Yi Z, Wisløff T, Johnson KD. Flem E, et al. Among authors: johnson kd. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar;22(2):315-326. doi: 10.1080/14737167.2021.1973893. Epub 2021 Sep 12. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 34488508

6

Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan.

Feemster KA, Kim Y, Abe M, Johnson K, Sasaki S. Feemster KA, et al. Expert Rev Vaccines. 2022 May;21(5):589-590. doi: 10.1080/14760584.2022.2036127. Epub 2022 Feb 16. Expert Rev Vaccines. 2022. PMID: 35172667 No abstract available.

7

Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland.

Deb A, Guggisberg P, Mutschler T, Owusu-Edusei K, Bencina G, Johnson KD, Ignacio T, Mathijssen DAR, Qendri V. Deb A, et al. Among authors: johnson kd. Expert Rev Vaccines. 2022 May;21(5):711-722. doi: 10.1080/14760584.2022.2046468. Epub 2022 Mar 20. Expert Rev Vaccines. 2022. PMID: 35220875

8

Response to Vyse et al., "A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK".

Dawson R, Buchwald UK, Johnson KD, Spowart L. Dawson R, et al. Among authors: johnson kd. Expert Rev Vaccines. 2022 Jun;21(6):869-870. doi: 10.1080/14760584.2022.2047023. Epub 2022 Mar 22. Expert Rev Vaccines. 2022. PMID: 35285368 No abstract available.

9

Regional factors associated with pneumococcal vaccination coverage among U.S. adults with underlying chronic or immunocompromising conditions.

Liu J, Shoener Dunham L, Johnson KD. Liu J, et al. Among authors: johnson kd. Hum Vaccin Immunother. 2023 Dec 31;19(1):2194779. doi: 10.1080/21645515.2023.2194779. Hum Vaccin Immunother. 2023. PMID: 37038308 Free PMC article.

10

Pneumococcal vaccination coverage among US adults enrolled in Medicaid and newly diagnosed with underlying medical conditions.

Liu J, Johnson KD, Shoener Dunham L. Liu J, et al. Among authors: johnson kd. Expert Rev Vaccines. 2023 Jan-Dec;22(1):596-607. doi: 10.1080/14760584.2023.2226718. Expert Rev Vaccines. 2023. PMID: 37401893 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

276 results

Search Page